CARA Cara Therapeutics Inc

Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus in patients undergoing hemodialysis will be presented in a poster at the National Kidney Foundation Spring Clinical Meetings 2022 (SCM22), to be held April 6-10, 2022, in Boston, MA.

Details for the poster presentation are as follows:

Title: Reduction of Pruritus by Difelikefalin Correlates With Reductions in Markers for Pruritus and Inflammation in Subjects Undergoing Hemodialysis Poster Number: 207Date and Time: April 7, 2022, 6:00-7:30 p.m. ETPresenter: Shayan Shirazian, MD, Columbia University College of Physicians and Surgeons, New York, NY

The ePoster is available at: https://www.kidney.org/spring-clinical.

In addition, details for other posters highlighting KORSUVA injection are as follows:

Title: Effect of Treatment with Difelikefalin on Itch Severity in Patients with Chronic Kidney Disease-Associated Pruritus Measured by the Patient Global Impression of ChangePoster Number: 212

Title: Improvement in Itch-Related Sleep Disruption with Difelikefalin in Patients with Moderate to Severe Chronic Kidney Disease Associated Pruritus Undergoing Hemodialysis: A Post-hoc Analysis of an Open-Label, Multicenter StudyPoster Number: 261

Title: CKD-associated Pruritus After 12 Weeks of Therapy with Difelikefalin Among Hemodialysis Patients with Severe Pruritus: A Post-hoc Analysis of Phase 3 StudiesPoster Number: 262

About Cara Therapeutics

Cara Therapeutics is an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:Annie Spinetta6 Degrees973-768-2170aspinetta@6degreespr.com

INVESTOR CONTACT:Iris Francesconi, Ph.D.Cara Therapeutics203-406-3700investor@caratherapeutics.com